Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for RAVULIZUMAB
- ARTEMIS: A Phase 3 Study of Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
- Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
- This is a Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.
- Pharmacokinetic Study of Ravulizumab Administered Subcutaneously With Recombinant Human Hyaluronidase PH20 (rHuPH20) in Healthy Adult Volunteers
- A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH
- Phase 2/3 Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD
- A Study of a Single Subcutaneous Dose of ALXN1210 in Healthy Adult Participants
- A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants
- A Study of Multiple Doses of ALXN1210 in Healthy Adult Participants
- A Study of a Single Dose of ALXN1210 in Healthy Participants
- Ravulizumab-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Co
- Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
- BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy
- Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis
- Ravulizumab and COVID-19
- Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
- Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
- Study of Ravulizumab in Pediatric Participants With HSCT-TMA
- Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
- Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)
- mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)
- First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH
- An Efficacy and Safety Study of Ravulizumab in ALS Participants
- Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis
Clinical trials list
click for details